This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D80.1 | Synonyms: common variable immunodeficiency, CVID, acquired hypogammaglobulinemia, late-onset hypogammaglobulinemia
Common variable immunodeficiency (CVID) was first described in 1953 by Janeway and Gitlin, who reported cases of acquired hypogammaglobulinemia arising in adults. In 1962, a WHO expert committee then classified this group of diseases under the name 'common variable'. The name reflects that the clinical phenotype of the disease is diverse (variable) and that it is a heterogeneous group (common).
CVID is not a single-gene disease but a heterogeneous group of diseases sharing a common clinical·immunological phenotype (hypogammaglobulinemia, recurrent infections, failure of antibody production). Through the 1970s~1990s, defects in B-cell differentiation and antibody production were established as the core pathogenesis of CVID.
Since the 2000s, variants in various genes such as ICOS, CD19, TACI (TNFRSF13B), BAFF-R, CD81, NFKB1, NFKB2, LRBA, CTLA4, PIK3CD have been reported as causes of CVID-like phenotypes. However, the causative gene still often cannot be identified in most CVID patients, so it is understood as a syndrome with heterogeneous pathogenesis.
In Korea, diagnosed cases of adult CVID began to be reported from the late 1990s, and it is now recognized as the most common form of primary immunodeficiency in adults. CVID clinical practice guidelines are being developed by the Korean immunology society and rare disease-related societies.
CVID is not a single-gene disease, and patients explained by currently known causative gene variants make up only about 20~25% of all CVID. In the remaining 75~80%, the causative gene is unclear.
TACI is a receptor involved in B-cell survival and antibody class-switch recombination. TACI variants are found in about 8~10% of CVID patients and occur as heterozygous variants (CVID, incomplete penetrance) and homozygous variants (more severe).
ICOS is a costimulatory molecule expressed on activated T cells that promotes antibody class-switch recombination through interaction with B cells. Homozygous loss-of-function variants in ICOS cause failure of T-cell-dependent antibody production. NFKB1 (p50) heterozygous loss-of-function variants are one of the most common single genetic causes of adult CVID, accounting for about 2~10% of all CVID.
LRBA deficiency and CTLA4 heterozygous loss-of-function variants cause CVID-like phenotypes combining autoimmunity and immunodeficiency. Gastrointestinal autoimmunity, granulomatous disease, and cytopenias are particularly prominent.
Depending on the causative gene, inheritance varies: autosomal dominant (NFKB1, CTLA4, CARD11 heterozygous variants), autosomal recessive (ICOS, LRBA, etc.), and complex inheritance (TACI, NFKB2). Despite a strong genetic contribution in most CVID patients, no clear single-gene cause is found.
In about 10~20% of CVID patients, family members with other immunodeficiencies (IgA deficiency, CVID, etc.) are identified. IgA deficiency and CVID are thought to belong to the same genetic spectrum.
Incomplete penetrance, in which only some carriers of heterozygous TACI or NFKB1 variants express the CVID phenotype, is characteristic. This suggests that environmental factors or other genetic variants additionally contribute to disease onset.
CVID is one of the most clinically important and common forms of primary immunodeficiency disease. Its prevalence is estimated at 1/25,000~1/50,000. Relatively high prevalence is reported in Europe (especially Western Europe), and it tends to be reported somewhat lower in Asia.
Age at diagnosis of CVID shows two peaks: the first at ages 1~5 and the second in adulthood in the 20s~30s. The latter is more common, and the mean time to diagnosis can reach 5~10 years.
The male-to-female ratio is nearly equal (1:1). This is one of the epidemiological differences from XLA.
In Korea, CVID is the most common form of primary immunodeficiency in adults. The exact prevalence is unknown, but analysis of health insurance claims data suggests that a considerable proportion of patients with primary immunodeficiency D80 codes have CVID. Newly diagnosed patients are increasing owing to improved access to specialized immunology clinics and greater awareness.
The core pathogenesis of CVID is that mature B cells (naive B cells) are present but, in response to antigen stimulation, terminal differentiation into memory B cells and plasma cells (antibody-secreting cells) does not occur. Unlike XLA, this is not a block in B-cell development itself but a defect in functional maturation in the periphery.
A marked reduction of memory B cells (CD27+), especially switched memory B cells (CD27+IgD-IgM-), is characteristic in CVID patients. The degree of reduction in switched memory B cells correlates with prognosis and the risk of complications.
In addition to defects of B cells themselves, dysfunction of T helper cells (Tfh, follicular helper T cells) and defective T-B cell interaction play important roles in CVID pathogenesis. Abnormal signaling of cytokines that promote B-cell survival and differentiation, such as BAFF and APRIL (TACI, BAFF-R variants), contributes to failure of B-cell maturation.
Recurrent bacterial respiratory infections (sinusitis, pneumonia, bronchitis) are the most common symptom. Infections due to Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus predominate, and a pattern of recurrence after treatment is characteristic. Gastrointestinal infections (Giardia lamblia, Campylobacter) and chronic diarrhea are also common.
Autoimmune disease develops in about 20–25% of CVID patients. Autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia, rheumatoid arthritis-like arthritis, autoimmune thyroid disease and others occur.
Non-infectious granulomas develop in about 8–22% of CVID patients. Granulomas form in the lungs, liver, spleen and lymph nodes, causing organ dysfunction. Sprue-like enteropathy, inflammatory bowel disease-like lesions, chronic diarrhea, malabsorption, weight loss and nutritional deficiencies may accompany it.
In CVID patients, the risk of lymphoma (B-cell lymphoma, especially MALT lymphoma) and gastric cancer (associated with chronic Helicobacter pylori infection) is increased compared with the general population.
Unlike XLA, lymphadenopathy and splenomegaly are commonly observed in CVID. Rhinorrhea due to chronic sinusitis, sequelae of chronic otitis media and abnormal breath sounds due to bronchiectasis are found. In granulomatous disease, hepatosplenomegaly and lymph node enlargement are prominent.
Serum IgG < 5 g/L (2 SD or more below the lower limit of normal for age), with IgA and IgM also markedly reduced. Specific antibody responses after vaccination (pneumococcal, tetanus vaccines) are markedly impaired. Peripheral blood B cells are normal or reduced, and reduced switched memory B cells (CD27+IgD-) are characteristic. T-cell numbers and function are basically normal, but reduced CD4+ T cells are observed in some.
Chest CT: bronchiectasis, granulomatous lung nodules, lymphocytic interstitial pneumonia (LIP) pattern. Abdominal CT/ultrasound: splenomegaly, lymphadenopathy, gastrointestinal wall thickening. FDG-PET: used to differentiate lymphoproliferative lesions and lymphoma.
CVID should be suspected in the following situations: recurrent bacterial respiratory infections in adults; especially recurrent pneumonia due to the same organism; unexplained hypogammaglobulinemia; autoimmune cytopenias accompanied by susceptibility to infection; a family member with primary immunodeficiency or IgA deficiency.
Quantification of serum IgG, IgA and IgM is the basic screening test. CVID is suspected when IgG < 5 g/L with reduced IgA and/or IgM. Tests to exclude secondary causes (malignancy, drugs, protein loss, etc.) are performed at the same time.
Specific antibody titers are measured 4–6 weeks after pneumococcal polysaccharide vaccine (23-valent) and tetanus vaccine. Failure of antibody response is an important functional criterion for the diagnosis of CVID.
The diagnosis is made when ① age 4 years or older, ② serum IgG 2 SD or more below the lower limit of normal for age + reduced IgA and/or IgM, ③ exclusion of secondary causes, and one or more of ④ failure of antibody response to T cell-dependent and -independent antigens and ⑤ abnormal B-cell maturation/plasma cell differentiation are met. A symptom period of 2 years or more before diagnosis is required (to exclude transient hypogammaglobulinemia of infancy).
Secondary hypogammaglobulinemia due to malignant lymphoma, chronic lymphocytic leukemia (CLL), protein-losing enteropathy, nephrotic syndrome, immunosuppressants or rituximab administration is excluded.
An NGS panel or whole-exome analysis including known genes that cause a CVID-like phenotype (ICOS, TACI, CD19, CD81, NFKB1, NFKB2, LRBA, CTLA4, PIK3CD, etc.) is performed.
IVIG (400–600 mg/kg every 3–4 weeks) or SCIG is the standard treatment. The goal is maintaining an IgG trough of 8–10 g/L, and a higher target is set when there are pulmonary complications. CVID patients must maintain IgRT for life.
Corticosteroids, rituximab and mycophenolate mofetil are used for ITP and AIHA. In LRBA deficiency, abatacept (CTLA-4 Ig) is effective. Corticosteroids or rituximab are used for granulomatous lung disease.
LRBA deficiency: administration of abatacept or belatacept. PIK3CD gain-of-function variants (APDS): PI3Kδ inhibitors (leniolisib, idelalisib). These targeted therapies correct immune abnormalities in a cause-specific manner.
Metronidazole or albendazole for chronic Giardia infection. Gluten restriction in sprue-like enteropathy, and steroids if needed. Helicobacter pylori eradication therapy.
Since the introduction of IgRT, the life expectancy of CVID patients has improved greatly. In patients with only simple recurrent infections, a relatively normal quality of life can be maintained with appropriate IgRT and antibiotic treatment.
Granulomatous lung disease, chronic lung disease (bronchiectasis), autoimmune cytopenias, gastrointestinal complications and development of lymphoma worsen the prognosis. The risk of lymphoma in CVID patients is about 10–20 times that of the general population. The risk of death is relatively high in CVID with granulomas and CVID with autoimmune complications.
Regular pulmonary function tests, chest CT, abdominal imaging, blood counts, autoantibody tests, upper endoscopy (H. pylori surveillance) and the like are needed for long-term follow-up. Transition-period care in adult patients and psychosocial support are also important.
When a causative gene has been identified, family testing and genetic counseling are performed. In autosomal dominant forms such as NFKB1 and CTLA4, screening of children and siblings is recommended.
Maintaining adequate IgRT is the key to preventing infection. Inactivated vaccines can be given, but the immune response may be insufficient. Early screening for and eradication of Helicobacter pylori reduces the risk of gastric cancer.
Considering the increased risk of lymphoma in CVID patients, regular lymph node assessment and imaging tests when necessary are performed. Regular upper endoscopy is recommended to reduce the risk of gastric cancer.